These findings highlighted the ROCK2-LIMK1 pathway as a therapeutic target to provide dendritic spine resilience against Aβ, which could benefit cognitively normal patients that are at high risk for developing AD dementia. This evidence concerns the gene ROCK2 and Alzheimer disease.